PR Newswire - Innovent Announces Phase 3 RESTORE-3 Study of SYCU...
SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) SAN FRANCI...
Read More


ภาษาไทย
English